Evaluation of efficacy of Dimethyl Fumarate in stroke

Comparing the effect of Dimethyl fumarate and Placebo on infarct size and NIHSS score in acute ischemic stroke patients

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180224038841N1

Enrollment

Registered

2019-01-13

Start date

2018-12-31

Completion date

Unknown

Last updated

2019-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic Stroke.

Interventions

Intervention 1: Intervention group: Dimethyl fumarate 240mg , three times a day for one week. Intervention 2: Control group: Placebo , three times a day for one week.

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Patients at the age of 18-85 years old Patients with acute neurological symptoms who have been diagnosed as ischemic stroke by a neurologist

Exclusion criteria

Exclusion criteria: Patients with prior sensitivity to dimethyl fumarate Patients with serious infections Pregnancy and lactation Immunologic deficiencies in the past 6 months (i.e. cancer,lymphoma, HIV and viral hepatitis) Patients receiving rtPA Patients who undergo endovascular treatment Liver function test more than 2 times of normal range Initial WBC count under 3500 lymphopenia under 500

Design outcomes

Primary

Measure	Time frame
Infarct Size in Magnetic Resonance Imaging(MRI). Timepoint: An MRI at the beginning of the trial and a second one after 15 to 45 days from starting Dimethyl fumarate or Placebo. Method of measurement: using automatic softwares.;National Institute of Health Stroke Scale (NIHSS). Timepoint: at the beginning of the trial and 30 days after starting Dimethyl fumarate. Method of measurement: NIHSS checklist.	—

Measure

Time frame

Infarct Size in Magnetic Resonance Imaging(MRI). Timepoint: An MRI at the beginning of the trial and a second one after 15 to 45 days from starting Dimethyl fumarate or Placebo. Method of measurement: using automatic softwares.;National Institute of Health Stroke Scale (NIHSS). Timepoint: at the beginning of the trial and 30 days after starting Dimethyl fumarate. Method of measurement: NIHSS checklist.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Mehrdad Savar

Tehran University of Medical Sciences

mehrdad.savar@gmail.com+98 21 8822 0040

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026